Company Overview and News
Telecom giant Reliance Jio has introduced a special annual prepaid recharge plan where it will provide users upto 547.5 GB 4G data at a price of Rs 1,699. The data plan will be valid for one year, where users will get 1.5 GB high-speed data everyday along with other benefits such as unlimited free voice calls, free messages and access to a plethora of exclusive Jio apps such as Jio Music, Jio TV among others.
WallStars all show positive broker target price upsides. Top "safer" dividend Technology WallStar, Western Digital, showed a 74.88% gain. Top-ten averaged 50.24% per Broker estimates plus dividends. 7/10 leaders were oversold.
WSO LRCX WSO.B CY KLIC WDC STX TEL MCHP KLAC AMAT GRMN DTST UMC QCOM MXIM
WallStars all show positive broker target price upsides. Top WallStar Technology ten by net gains, STX, XRX, KLAC, CY, LRCX, RELL, CAMT, WDC, TIVO and XPER, averaged 61.15%, calculated 10/15/18.
LRCX CY XPER RELLB WDC STX KLAC XRX CAMT LYTS UMC NOK RELL TESS TIVO
Western Digital (WDC - Free Report) closed at $54.50 in the latest trading session, marking a +0.17% move from the prior day. This change outpaced the S&P 500's 0.59% loss on the day. Elsewhere, the Dow lost 0.35%, while the tech-heavy Nasdaq lost 0.88%.
LMT VBTX WDC WSFS WSFSL
Investors in Western Digital Corporation (WDC - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Oct 19, 2018 $85.00 Call had some of the highest implied volatility of all equity options today.
Western Digital (WDC - Free Report) closed at $55.65 in the latest trading session, marking a -0.84% move from the prior day. This move lagged the S&P 500's daily loss of 0.04%. At the same time, the Dow added 0.15%, and the tech-heavy Nasdaq lost 0.67%.
In one fell swoop, Intel (NASDAQ:INTC) reasserted itself back into the semiconductor discussion. For several months, all eyes zeroed in on Advanced Micro Devices (NASDAQ:AMD). Since the beginning of June, AMD has more than doubled. In sharp contrast, INTC stock has fallen nearly 17%.
WDC STX AMD INTC
We now partner with Financial Exchange Radio to produce a weekly segment with Seeking Alpha authors.
In the latest trading session, Western Digital (WDC - Free Report) closed at $58.02, marking a -0.94% move from the previous day. This move lagged the S&P 500's daily gain of 0.36%. At the same time, the Dow added 0.73%, and the tech-heavy Nasdaq lost 0.11%.
2018-10-01 247wallst - 1
The futures traded up big Monday morning as we start the final quarter of 2018. With some of the distractions starting to move out of the way, and the Federal Reserve rate increase on the books, Wall Street will be looking forward to the start of the third-quarter earnings reporting season. Add in Canada agreeing to a new trade deal, and stocks look ready to take off.
LOGM LRCX AMGN WDC TRI CIEN DLPH CMG NTGR
2018-10-01 marketwatch - 2
Mizuho analyst Vijay Rakesh defended Micron Technology Inc.'s MU, +0.53% stock on Monday, writing that the company was "a better house in a tough neighborhood" amid concerns about memory prices. Rakesh expects that DRAM prices could be down 3% or 4% in the calendar fourth quarter, but he predicts that prices could stabilize "earlier in the June quarter of 2018, providing a faster normalization for Micron.
LRCX MU WDC
Shares of Lam Research Corp. LRCX, +0.75% are down 0.5% in premarket trading Monday while shares of Western Digital Corp. WDC, +0.45% are down 1.1% after Mizhuo analyst Vijay Rakesh downgraded both stocks to neutral from buy due to NAND concerns. "We believe NAND ASP (average selling price) pricing will continue to decline at a low-double digit rate through 1Q19 and a high-single digit rate through 2019," he wrote.
Twitter Inc. just seized a title no company wants: the worst performer in the S&P 500 Index. Shares of the social-media giant dropped about 35 percent in third-quarter trading, which ended Friday — worse than every other company in the index. Twitter’s tough quarter was set off by a disappointing earnings report.
SQ SQNXF TWTR IPGP WDC
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to WDC / Western Digital Corp. on message board site Silicon Investor.
as of ET